skip-to-main

Great Britain

Resources for healthcare professionals

Resources for healthcare professionals

Spikevax bivalent Original/Omicron BA.4-5▼(50 micrograms/50 micrograms)/mL dispersion for injection

Spikevax bivalent Original/Omicron BA.4-5 is indicated as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Feb 23, 2023

Spikevax bivalent Original/Omicron BA.1▼(50 micrograms/50 micrograms)/mL dispersion for injection

A Conditional Marketing Authorisation (CMA) has been granted in the UK for Spikevax bivalent Original/Omicron as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Nov 28, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Nov 04, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 26, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 12, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 09, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 07, 2022

Spikevax▼(previously COVID-19 Vaccine Moderna)

Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 27, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 07, 2022

Northern Ireland

Resources for healthcare professionals

Resources for healthcare professionals

Spikevax bivalent Original/Omicron BA.4-5▼(50 micrograms/50 micrograms)/mL dispersion for injection

Spikevax bivalent Original/Omicron BA.4-5 is indicated for active immunizsation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Nov 28, 2022

Spikevax bivalent Original/Omicron BA.1▼(50 micrograms/50 micrograms)/mL dispersion for injection

Spikevax bivalent Original/Omicron BA.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against COVID-19.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Nov 28, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 29, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 21, 2022

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 12, 2022

Spikevax▼(previously COVID-19 Vaccine Moderna)

Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Direct Healthcare Professional Communication

Direct Healthcare Professional Communication

Sep 27, 2022

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store and include the vaccine brand and batch/Lot number if available. They can also be reported to Moderna using the Adverse Event Intake Portal or by calling 0800 085 7562.

To report a product quality complaint or for general medical information inquiries, please contact Moderna on 0800 085 7562 or at EMEAMedinfo@modernatx.com

Contact Moderna

    © 2023 Moderna, Inc.

    UK-COV-2100001 03/2023